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Abstract
A high fidelity transmural anisotropic ventricular tissue model consisting of
endocardial, mid myocardial, and epicardial myocytes were configured to investi-
gate drug interaction, such as Hydroxychloroquine (HCQ), under hypoxia condi-
tions without and with pro-arrhythmic comorbidity like hypokalemia in (a)
ventricular tissue b) its arrhythmogenesis for different dosages and (b) two differ-
ent pacing sequences (Normal and tachycardiac). In-silico ventricular modeling
indicates HCQ has an insignificant effect on hypoxia with and without
comorbidities, except in the combination of mild hypoxia with moderate hypokale-
mia condition and severe hypoxia with mild hypokalemia where it initiated a re-
entrant arrhythmia. Secondly, incorporating drug dosage variations indicates the 10
μMHCQ created PVCs for all settings except in severe hypoxia conditions where re-
entrant arrhythmia occurred. In addition to the dosage of HCQ utilized for treat-
ment, the pacing protocol also influences the appearance of re-entrant arrhythmia
only for severe hypoxia with 10 μM HCQ dosage alone. For all other conditions,
including tachycardiac pacing protocol, no arrhythmia occurred. These findings
infer that the arrhythmic fatality rate due to HCQ treatment for hypoxia can be
effectively alleviated by subtly altering or personalizing the dosage of HCQ and aid
in the treatment of hypoxia-induced symptoms caused by COVID.
Keywords: Hydroxychloroquine, Hypoxia, Hypokalemia, Azithromycin,
Ventricular Arrhythmia, Transmural Tissue, COVID-19
1. Introduction
Precision medicine is significantly focused and promoted due to the develop-
ment of next-generation sequencing, which implies high throughput and lower cost.
Even though molecular and cell biology has improved basic understanding of many
diseases, novel and pandemic diseases like Severe Acute Respiratory Syndrome
Coronavirus (SARS-CoV-2) have many unanswered questions on infection
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mechanism, progression, and impact of symptom-based treatment using “off label”
drugs. For instance, Hydroxychloroquine (HCQ), an antimalarial drug widely used to
boost the immune system, was attempted or explored towards treating COVID-19.
The US Food and Drugs Administration (FDA) and WHO initially approved HCQ as
an emergency medicine based on laboratory and clinical studies data. Irrespective of
earlier findings suggesting that long-term (over 5 years) intake of HCQ is likely to
contribute to the development of retinopathy, include QRS widening, QT interval
prolongation, ventricular arrhythmias like Torsades de pointes (TdP), hypokalemia
and hypotension [1, 2], in-vitro studies reported the potential activity of HCQ on
SARS-CoV-2 [3, 4]. On a positive note, in experiments performed on mouse atria,
Capel et al. [5] reported that HCQ acted as a bradycardiac agent (reducing the
spontaneous beating rate) in sinoatrial cells via a dose-dependent reduction of multi-
ple ionic currents: ‘funny’ current (I f ), L-type calcium current (ICaL) and rapid
delayed rectifier potassium current (IKr). Modeling of drug cardiotoxicity at the
cellular level focuses predominantly on reducing IKr current and leads to prolongation
of APD in cells and QT interval in whole heart level, thereby leading to arrhythmias
like TdP [6]. However, a clinical study in France [7] reported that either HCQ alone
or in combination with azithromycin is efficient in treating COVID-19. However,
Sarkar et al., 2012 [8] reported that one population of cell differs from another (i.e
healthy vs. diseased) and electrophysiological variability manifests at each level, from
molecular, cellular, organ, and organism level. Hence, considering the outcome of
previous clinical evidence of HCQ on normal cells may be inadequate to provide the
exact impact of the effect of HCQ on virus infected cells or tissue. As our particular
interest is in the human cardiac system; specifically electrophysiology, we wish to
emphasis the variability of COVID-19 in cardiac system. Clinical observations
reported by Mercuro et al. [9] shows the median baseline QTc was 455 ms in 90
COVID-19 patients and in presence of HCQ, it increased to 473 ms. Among those
who received HCQ alone, 19% had QTc prolongation of 500 ms or more, 13% had a
change inQTc of 60 ms or more and 1 case of Torsade de Pointes (TdP) was reported.
Thus it’s very evident that investigating and understanding the cardiac manifestation
mechanism due to medication like HCQ drug is critical.
Li X et al.’s study in 2019 on 175 patients with COVID-19 reported that, 39
patients had severe hypokalemia (under 3 mmol/L), 69 had moderate hypokalemia
(3–3.5 mmol/L) and 67 were normokalemia (over 3.5 mmol/L) [10]. He et al., [11]
proposed that ACE-2 signaling pathways may play a role in cardiac injury while
hypoxemia caused by COVID-19 may cause damage to myocardial cells. Severe
hypoxemia occurring in lungs of COVID-19 patients has been linked to loss of lung
perfusion regulation and hypoxic vasoconstriction [12]. Acute viral infections like
that of COVID-19 have been known to cause type 1 or 2 myocardial infarction
though the frequency of STE in these patients is unclear [13]. All these resulted in
the liberal use of HCQ globally, in spite of contempt of paucity of evidence and
adverse effect [3] for a short span of time.
During this situation, Wang et al. reported that treating COVID-19 with a
combination of HCQ and AZM elicited electrical alternates, re-entrant circuits and
the wave breaks [14]. Further, this clinical study reported that different dosages of
HCQ blocked the various ionic currents: INa, ICaL, IKr and IK1 with different
intensity. Based on the [15] finding, HCQ treatment for COVID-19 lead to ventric-
ular arrhythmia and death in hospitalized COVID patients, In May 2020, WHO
suspended the emergency usage of HCQ; later, this study article was retracted due
to reporting of fabricated data. There is no clinical evidence that provides the
detailed mechanism of HCQ’s safety or adversity, particularly the cardiac cell and
tissue, i.e., under what scenarios the target drug interaction may cause arrhythmias
in patients.
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Although various researchers have attempted to study the pharmacokinetics of
HCQ: it’s the inhibitory mechanism on human cells under normal conditions and
various abnormal pathologies, for the reasons noted, it is critical to zero down the
effect of a drug and explains its response range. Such comprehensive study, either
using in-vivo or clinical studies, is difficult in a short period with present-day
technology. In this situation, computational models can help to elucidate and over-
come the following aspects:
• The effect of COVID-19 infection on electrophysiological properties of
ventricular tissue
• Lack of clinical evidence that provides a detailed influence of HCQ on COVID-
19 infected cardiac tissue. For example, changes in ECG, mechanism, and
potential severity of ventricular arrhythmias like TdP
• Mechanistic understanding of HCQ on ventricular tissues under comorbid
scenarios, such as varying intensities of hypokalemia.
To address the above gaps, we develop a 2D transmural anisotropic ventricular
tissue model framework that can help in primarily understanding the COVID-19
effect on the ventricular tissue, including the response to pharmacological agents
like HCQ. Two variations of COVID-19; mild and severe infection are explored.
Secondly, different levels of hypokalemia (mild, moderate and severe) along with
COVID-19 are introduced one at a time to understand its effect on ventricular tissue
In each case, the variations in the QT interval and T-peak are recorded. Finally, the
tissue is excited with premature stimuli to analyze under which of the above three
conditions the tissue becomes pro- arrhythmic. Although studies have established
that HCQ induces QT prolongation, TdP arises only in certain scenarios. This study
is an attempt to address the possibilities under which an arrhythmia is generated at
the tissue level in presence of the above mentioned conditions.
2. Transmural cardiac tissue model
The 2D transmural section of the ventricular wall, is represented by an array of
250  100 cells, consisting of endocardial (endo), midmydocardial (M) and
Condition Ionic current Change
HCQ IKr 35% reduction
ICaL 12% reduction
Hypokalemia1 Kþo 85% reduction
Hypokalemia2 Kþo 55% reduction
Hypokalemia3 Kþo 45% reduction




Severe COVID-19 ATP½ i 5 mM
k0:5 0.250
Table 1.
Change in parameters for different conditions.
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epicardial(epi) cells. The depolarisation and repolarisation patterns generated from
the tissue are validated by simulating pseudo ECGs. The action potentials of differ-
ent types of cardiomyocytes are described by the Ten Tusscher (TP06) model [16].
A stimulus current of amplitude 52 μA is applied for 1 ms is used to excite specific
cell. The parameters of the model, tissue characteristics and integration scheme are
adopted from Priya et al., 2017 [17]. The change in cardiomyocyte’s ionic current
parameters in the various configurations: hypokalemia and COVID-19 are summa-
rized in Table 1.
As COVID-19 has been linked to causing hypoxemia [11], which in turn leads to
hypoxia, this condition was included in the cardiac myocytes by increasing intra-
cellular ATP concentration which would in turn lead to activation of an ATP sensi-
tive potassium current. Using the formulation of Shaw and Rudy [18], ATP









Vm  Ekð Þ (1)
where Gk,ATP is the maximum conductance of IATP current and has a value of 3.9
nS=cm2, H and n have a value of 2 and 0.24 respectively. The intracellular ATP
concentration ( ATP½ i) under normal condition is 6.8 mM, but it decreases to
5.5 mM in mild hypoxia and 5 mM in severe hypoxia respectively. Similarly, k0:5 is
0.042 for normal condition, 0.125 and 0.25 for mild and severe hypoxia respectively
[19]. Henceforth, in this study, hypoxia would be referred as COVID-19 condition.
Further, reduction in the rapid delayed rectifying potassium current (IKr) and ICaL
by 35% and 12% respectively in atrial cells as reported by [5] is adapted in our
model.
To investigate the benefits and adverse effects of HCQ under control, COVID-19
and comorbid hypokalaemia, the ion channel variations corresponding to these
conditions were included in the cells of the tissue one at a time, as reported by [10],
the extracellular potassium concentration (Koþ) is reduced by three stages: 85% as
hypokalemia1 (mild), 55% as hypokalemia2 (moderate) and 45% as hypokalemia3
(severe). A regular pacing pulse of 800 ms (corresponding to 75 beats per minute)
is applied in the tissue, and the corresponding voltage propagation is analyzed.
Further, pseudo ECGs are generated for each of the clinical conditions. The varia-
tion in ECG, in particular the QT interval and T-wave morphology, both without
and with HCQ and in presence of comorbidity is considered for analysis. Further-
more, the tissue is stimulated with premature stimuli in between the normal beats
to study which conditions can initiate or sustain an arrhythmia.
3. Cardiac tissue mechanism(s) in control, COVID-19 and hypokalemia
conditions, and with HCQ
To understand the spatiotemporal mechanism of the cardiac tissue, the lower
leftmost corner (Cells 1:10,1:2) of the transmural tissue is stimulated. As a result of
this stimuli, a convex wavefront propagates from the endo to mid and epi layer
from the bottom to the top of the tissue. The repolarisation occurs first in the epi
and endo layers, and M-cells in the mid layer are the last to repolarise. Normalized
pseudo ECGs are synthesized from this tissue.Mild and severe COVID-19 conditions
are introduced in the tissue to study its effect without and with HCQ. Furthermore,
a comorbidity like hypokalemia is included to understand its influence on COVID-
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19 conditions. Pseudo ECGs are synthesized for each of these conditions and the QT
interval and T-peak are tabulated in Table 2.
In control conditions, a 0.345 sec QT interval and 0.2265 mV T-peak occurs.
While in mild COVID-19, the QT interval and T-peak decreases by 5.79% (0.325)
sec and 33.33% (0.151 mV) respectively as seen in Figure 1(i). In combination with
HCQ, the QT interval slightly increases by 1.45% (0.340 sec) and T-peak rises by
20.08% (0.181 mV) in comparison with no HCQ. However, it does not reach the
control values. Under severe COVID-19 conditions, the QT interval is further
reduced by 20.29% (0.275 s) and a negative T-wave peak of 0.17 mV is observed
along with a QT depression. This negative T-peak might be representative of ische-
mia in clinical ECG recordings. In contrast, the effect of HCQ in severe COVID-19 is
negligible with unchanged QT interval and slight increase in T-peak (0.153 mV).
Here,we have considered a pacing interval of 800 msec (i.e HR is 75 beats/min), so
the Bazett QTc interval is 0.363 sec and 0.307 sec in mild andsevere COVID-19
conditions. Anttonen et al., [20] reported that an individual’s QTc interval < 320
msec is a low rate of all-cause mortality, from which we infer that a patient with
severe hypoxia is thus not at high risk of mortality from cardiac failure or disorder;
unless and otherwise in presence of other comorbidities. On adding HCQ, 0.380 sec
Condition QT interval (s) T-peak (mV)
Control 0.345 0.2265
Mild COVID-19 0.325 0.152
Severe COVID-19 0.275 0.170
Mild COVID-19 with HCQ 0.340 0.181
Severe COVID-19 with HCQ 0.275 0.153
Hypokalemia1 0.355 0.229
Hypokalemia1 with HCQ 0.375 0.265
Hypokalemia2 0.380 0.217
Hypokalemia2 with HCQ 0.410 0.255
Hypokalemia3 0.390 0.210
Hypokalemia3 with HCQ 0.425 0.246
Hypokalemia1a and Mild COVID-19 0.335 0.127, 0.153
Hypokalemia1 and Mild COVID-19 with HCQ 0.350 0.186
Hypokalemia1 and Severe COVID-19 0.285 0.16, 0.087
Hypokalemia1 and Severe COVID-19 with HCQ 0.285 0.14
Hypokalemia2 and Mild COVID-19 0.355 0.141
Hypokalemia2 and Mild COVID-19 with HCQ 0.38 0.174
Hypokalemia2 and Severe COVID-19 0.300 0.156
Hypokalemia2 and Severe COVID-19 with HCQ 0.305 0.126
Hypokalemia3 and Mild COVID-19 0.365 0.133
Hypokalemia3 and Mild COVID-19 with HCQ 0.395 0.168
Hypokalemia3 and Severe COVID-19 0.31 0.155
Hypokalemia3 and Severe COVID-19 with HCQ 0.32 0.121
Table 2.
Pseudo ECG parameters: T-peak and QT interval duration as a metric for assessing the effect of COVID-19,
other comorbidity and in presence of HCQ.
5
A High Fidelity Transmural Anisotropic Ventricular Tissue Model Function to Investigate…
DOI: http://dx.doi.org/10.5772/intechopen.99873
QTc interval increased in mild, while it remains the same in severe hypoxia condi-
tions. Mercuro et al. [9] reported that in 90 COVID-19 patients, the median baseline
QTc was 455 (430–474) ms in control vs. 473 [454–487] ms in HCQ conditions. The
QTc values reported in our study are lower than those observed clinically due to the
limitation of considering only a segment of the ventricle. However, the percentage
increase in APD between control and HCQ in the clinical study of Mercuro et al. is
3.95%. An increase of 4.68% QTc is observed, on comparing themild COVID-19 and
on HCQ inclusion.
Figure 1(ii-v) shows the pseudo ECGs generated for the different combinations
of Hypokalemia and COVID-19 as well as in presence of HCQ. In comorbid hypo-
kalemia1 condition as seen in Figure 1(ii), the QT interval increases by 2.89%
(0.355 s), while the peak amplitude of T-wave increases only by 1.10% (0.229 mV),
almost similar to control condition. When exposed to HCQ, the QT interval
increases by 8.69% (0.375 ms) and T-peak amplitude increases by 16.99%
(0.265 mV) in comparison to control. But, when infected by mild COVID-19, the
QT interval decreases by 2.89% (0.335 s), yet a notched T-wave appears with the
first T-peak of 0.127 mV and second peak of 0.153 mV is observed. On adding HCQ,
the notched T-wave are replaced by positive T-waves. The QT interval is increased
by 1.45% (0.350 mV) and T-peak is reduced by 17.88% (0.186 mV) in comparison
with control. In contrast to control condition, pre-existing hypokalemia1 with
severe COVID-19 reduces the QT interval by 17.39% (0.285 s) and a negative T-
peak of 0.16 mV is observed i.e. suggestive of ischemia as seen in Figure 1(iii). HCQ
drug does not have any noteworthy effect other than slight reduction of T-peak to
0.14 mV.
In hypokalemia2 in Figure 1(iv), the QT interval is prolonged by 10.14%
(0.380 ms) but T-peak reduced by 4.19% (0.217 mV) is observed, and HCQ
Figure 1.
Pseudo ECGs generated in control and in presence of HCQ under (i)mild and severe COVID-19 (ii)
Hypokalemia, (iii)Hypokalemia1 and COVID-19, (iv)Hypokalemia2 and COVID-19 and (v)
Hypokalemia3 and COVID-19.
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exposure increases 18.84% (0.410 ms) QT interval with 12.58% (0.255 mV) increase
in T-peak. On considering hypokalemia2 and mild COVID-19, the QT interval
increases by 2.89% (0.355 s) while T-peak reduces by 37.74% (0.141 mV) in com-
parison to control, and HCQ inclusion, prolonged QT interval by 10.14% (0.380 s),
but reduce the T-peak by 23.17% (0.174 mV). Similar to the hypokalemia1 and
COVID-19 scenario, the hypokalemia2 and severe COVID-19 we observed, a nega-
tive T-peak (0.156 mV) with 13.04% (0.300 s) QT interval reduction. Here too,
HCQ has no significant effect, other than a slight increase in the QT interval
(0.305 s) and T-peak (0.126 mV).
Finally, in hypokalemia3, Figure 1(v), the QT interval is prolonged by 13.04%
(0.390 ms) while the T-peak is reduced by 7.28% (0.210 mV), similar to hypokale-
mia2 observation. In HCQ presence, the QT interval increases by 23.18% (0.425 ms)
and the T-peak increases by 8.61% (0.246 mV) comparing to control. Mild COVID-
19 has the effect of increasing the QT interval by 5.79% (0.365 s) and reducing the
T-peak by 41.28% (0.133 mV). HCQ treatment further prolongs the QT interval by
14.49% (0.395 s) and reduces T-peak by 25.82% (0.168 mV). Similarly for severe
COVID-19 with hypokalemia3, a negative T-peak of 0.155 mV with 10.14% QT
interval reduction (0.310 s) is observed, and on adding HCQ, the QT interval
increases to 0.320 s and the T-peak becomes slightly less negative at 0.121 mV.
Thus, it can be summarized that irrespective preexisting hypokalemic’s severity
level, severe COVID-19 can proliferate the risk factor due inverted T-wave pres-
ence, that implies the ischemia occurrence.
3.1 Arrhythmogenesis effect of HCQ on COVID-19 infected tissue including
and excluding hypokalemia
3.1.1 Premature pacing sequence protocol
The scientific community has well accepted that early or late repolarization of
the ventricular myocytes manifest due to ionic imbalances and are regulated by
different mechanisms; which are involved in or responsible for various life-
threatening cardiac diseases. Further, to understand the arrhythmia mechanism,
cardiac tissue is paced with premature beats (PBs) in between the normal pacing
beats of 800 ms. Three consecutive PBs (single or two PBs are not effective in
creating an arrhythmia) are applied to strive in initiating an arrhythmic pattern.
PBs duration is determined as the period the endo cell comes out of the refractory
state and are re-excitable. The subsequent sections describe the possibility of
occurrence of arrhythmia on pacing the tissue with PBs in mild and severe COVID-
19 configurations, comorbid hypokalemia and on inclusion of HCQ.
3.1.2 Arrhythmogenesis response for mild and severe COVID-19 cardiac tissue: when
treated with HCQ
Figure 2 shows the pseudo-ECG on including mild and severe COVID-19 condi-
tions and on HCQ exposure to cardiac tissue. Under mild COVID-19, three PBs of
each 295 msec duration are applied after the first beat. The cardiac tissue’s mid cells
are in a repolarising state when the first PB is applied. This causes the depolarisation
from the first PB to travel upward along the endo layer and later depolarise the mid
and epi layer, which results in a negative T-wave (Figure 2(i)). The depolarisation
wavefront from the second PB is not able to excite the cells in the epi layer as they
are in a refractory state and this appears as a STE. Further, when the third PB
occurs, an inverted T-wave is created as the mid and epi cells depolarize simulta-
neously. Later in both cases, normal pacing pulses resumed at 1.6 sec and HCQ
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presence shows a similar trend. This finding is in line with Wang et al. [14] study,
where a 10 μM HCQ dosage prolonged the cells APD but did not induce an
arrhythmia on decreasing the pacing interval.
In severe COVID-19, the three PBs are applied for every 250 msec, that leads to
increase in the negative T-peak amplitude, due to the changes in depolarisation and
repolarisation pattern; similar to the first PB in mild COVID-19 case. The first and
third PBs increases the amplitude of negative T-peak compared to the second PB.
The normal ECGs are resumed at 1.6 sec in both scenarios. Results infers that an
inverted T-wave morphology (representative of ischemia) can be used as a bio-
marker for severe COVID-19 conditions. Further, HCQ drug causes negligible mod-
ifications in the voltage propagation patterns and no effect has been observed in the
ECG compared with control.
3.1.3 Arrhythmogenesis mechanism for the pre-existing Hypokalemia of COVID-19
cardiac tissue: when treated with HCQ
To investigate the impact of COVID-19, pseudo ECGs a shown in Figure 3 are
generated on pacing the tissue with PBs in the presence of different degree of
Hypokalemia, severity of COVID-19 and on including HCQ.
Hypokalemia1 Infected with COVID-19, with and without HCQ: The tissue is
regularly paced every 800 msec. After the first pacing pulse, three premature beats
each of 305 msec duration are applied at the same pacing site as indicated in
Figure 3(i). It is observed that in the case of hypokalemia1, reentrant activity is
generated from 0.37 sec to 1.39 sec and normal beats are resumed from 1.6 sec. On
including HCQ and applying three PBs at 325 msec duration each, reentrant activity
is generated from 0.38 sec to 2.2 sec and it resumes to normal from 2.4 sec. Hence,
there is a 43.96% risk in the arrhythmic activity.
In Figure 3(ii), hypokalemia1 andmild COVID-19 conditions are included in the
tissue, three PBs each of 295 msec are applied after the first beat. The regular pacing
interval is 800 msec. When the tissue is excited due to the first PB, the cells in top of
endo layer and those in mid and epi layers are in repolarising state. Thus, the
wavefront from first PB travels upwards along the endo layer and propagates into
the mid and epi layer. When the second PB occurs at 0.59 sec, the mid and epi cells
are in repolarising state, thus the wavefront propagates along the endo layer and
then enters into the mid and epi layer from the bottom once they come out of
refractory state. A similar excitation pattern is observed after the third PB is
applied. These changes in depolarisation and repolarisation appears as an
arrhythmic-like activity from 0.355 sec to 1.24 sec in the pseudo ECG and normal
beats are resumed from 1.6 s. Therefore, it is to be noted that the reentrant activity
is not generated. On including HCQ at 305 msec duration of three premature beats,
Figure 2.
Pseudo ECG for i)mild COVID-19 and HCQ ii)severe COVID-19 and HCQ.
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a similar type of waveform is generated from 0.365 sec to 1.395 sec and normal beats
are resumed from 2.4 sec. On the other hand, hypokalemia1 infected with severe
COVID-19, the absence of HCQ creates a reentrant pattern from 0.315 s to 1.045 s
on pacing the tissue with 3 PBs each of 250 ms duration as seen in Figure 3(iii). On
including HCQ and applying the same pacing protocol, reentry is not generated in
the tissue. However, the excitation by the PB creates a similar appearance of ECG
waveform. This difference can be seen in Figure 3(iii). This shows that HCQ plays a
vital role in pre-exisitng hypokalemia1 with COVID-19 cases.
Hypokalemia2 Infected with mild COVID-19, with and without HCQ: Apply-
ing three PBs each of 330 msec duration in between the normal pacing pulses in
presence of hypokalemia2 does not generate any re-entrant activity as seen in
Figure 3(iv). The third PB at 0.99 sec generates a negative T-peak of 0.056 mV and
the normal activity is resumed from 1.6 sec. However, in presence of HCQ with
355 msec PBs, reentrant activity is generated from 0.4 sec to 1.34 sec and the regular
pacing sequence is resumed at 1.6 sec.
Hypokalemia2 and mild COVID-19 conditions are included in the tissue and
paced with PBs as shown in Figure 3(v). Reentrant activity is observed in the
pseudo ECG after pacing with three PBs each of 300 msec duration from 0.355 sec
to 0.935 sec. In order to understand the detailed arrhythmogenesis mechanism in
hypokalemia2 with mild COVID-19 conditions, voltage maps of cardiac tissue are
shown in Figure 4 starting from the application of the first PB at 0.300 sec. At this
time, the endo cells at the top and the M-cells and epi cells are still in repolaring
state. The depolarisation wave created from this first PB is shown in Figure 4(a) at
0.31 sec. This wave proceeds upwards along the endo layer by which time the M-
cells are returning to rest state as seen in Figure 4(b). The wavefront then travels
along the entire length of endo layer and reenters the mid and epi layers as seen in
Figure 3.
Pseudo ECG for i)Hypokalemia1 and treated with HCQ, ii)Hypokalemia1 with mild COVID-19 and treated
with HCQ iii)Hypokalemia1 with severe COVID-19 and treated with HCQ ii) iv)Hypokalemia2 and treated with
HCQ with HCQ, v)Hypokalemia2 with mild COVID-19 and treated with HCQ vi)Hypokalemia2 with severe
COVID-19 and treated with HCQ, vii)Hypokalemia3 and treated with HCQ, viii)Hypokalemia3 with mild
COVID-19 and treated with HCQ ix)Hypokalemia3 with severe COVID-19 and treated with HCQ.
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Figure 4(c) and (d). This wavefront then reenters into the endo layer at the bottom
of the tissue and travels upwards along the endo layer as seen in Figure 4(e) and
(f). The second PB is applied at 0.6 sec and during this time the endo cells are
already depolarised. This wavefront re-enters into the mid and epi layers by which
time the mid and epi cells have repolarised as seen in Figure 4(g)–(i). The
wavefront depolarises cells in mid and epi layers and reenters endo layer as seen in
Figure 4(j)–(k). The third PB is applied at 0.9 sec and the cells at the pacing site are
already depolarised. The cells start repolarising from the epi, mid and endo with
cells at the bottom of the endo and mid layer repolarising last as seen in Figure 4(ii)
(l)–(n). All the cells finally repolarise at 1.085 sec.
On adding HCQ and pacing the tissue with 3 PBs, each of 330 msec duration, in
between the regular pacing interval of 800 msec, although arrhythmic-like activity
is observed from 0.37 sec to 1.295 sec in the pseudo ECG, this is due to the
depolarisation and repolarisation sequence of the cells in the tissue and not because
of reentry. Normal beats are resumed from 1.6 sec.
In case of severe COVID-19 conditions, the application of three PBs each of
250 msec, gives rise to the pseudo ECG shown in Figure 3(vi). The excitation of the
first and third PB appear representative of an STE. On introducing HCQ, a similar
ECG waveform is observed and no reentry of wavefront is observed.
Hypokalemia3 Infected with COVID-19, with and without HCQ: Similarly, in
case of hypokalemia3, reentrant activity is not generated when pacing the tissue
with 335 msec duration PBs as seen in Figure 3(vii). Inclusion of HCQ causes
reentrant activity to appear from 0.415 sec to 1.45 sec on pacing with PBs of
355 msec duration. The regular pacing sequence is resumed at 1.6 sec. Even though
HCQ drug is not intended for hypokalemia treatment, here we attempted to under-
stand the role of HCQ in hypokalemia. Result infers that the presence of HCQ is
pro-arrhythmic under all severity levels of hypokalemic and would have to be used
with caution in such scenarios.
Figure 3(viii) shows the pseudo ECG on including Hypokalemia3 and mild
COVID-19 conditions in the tissue and pacing with PBs. No reentrant activity is
observed even after pacing with three PBs each of 310 msec duration. Similarly, on
adding HCQ and pacing the tissue with 3 PBs, each of 330 msec duration, in
between the regular pacing interval of 800 ms, no reentrant activity is generated.
Normal beats are resumed from 1.6 sec. Under hypokalemia3 and severe COVID-19
Figure 4.
Voltage maps on applying PBs in Hypokalemia2 with mild COVID-19.
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conditions, the application of three PBs each of 265 ms, gives rise to the pseudo ECG
shown in Figure 3(ix). Similar to earlier case of hypokalemia2 and severe COVID-
19, the excitation of the first and third PB appear representative of an ST-elevation
as the epi cells are not depolarised.
4. Dosage effects in COVID-19 infected cardiac tissue: HCQ and with
AZM
To understand the influence of different dosages of HCQ alone and in combina-
tion with AZM in the COVID-19 infected cardiac tissue, the cardiomyocyte’s ionic
current parameters are varied based on the clinical study reported by Wang et al.,
[21], and listed in Table 3. To the best of the author’s knowledge, prior art studies
have not considered the role of temperature (fever) arising due to COVID-19; in
this study, we configure the computational model of the ventricular tissue with an
elevated temperature of 313.15 Kelvin.
The ECG parameters, namely QT interval, T-peak and QRS duration are
extracted from the pseudo ECG and tabulated in Table 4. Here, the cardiac tissue is
paced with three consecutive premature beats (PBs) with a regular pacing interval
of 800 ms (75 bpm). Initialization of the first PB in each case is determined as the
endo cell’s period comes out of the refractory state and re-excitable. The consecu-
tive beats get reduced by 10 msec. We further extended it in the presence of PBs in
mild and severe COVID-19 to determine the arrhythmia occurrence for various HCQ
dosages and with AZM.
In the control ventricular condition, the QT interval is observed to be 0.350 sec,
T-peak is 0.232 mV and the QRS duration is 0.07 sec. In the case of adding 1 μM, 10
μM, and 100 μM HCQ, the QT interval increases by 1.42%, 11.43%, and 44.28%,
respectively, as shown in Figure 1(i). However, the T-peak decreases by 10.35%
and 0.85% under 1 μM and 100 μM HCQ, but, in 10 μM, it increases by 18.10%.
Also, QRS duration increased by 7.14% in both 1 μM and 10 μM HCQ and by 21.4%
in 100 μM HCQ. Application of PBs in the 1 μM HCQ or 10 μM HCQ configuration,
it gives rise to premature ventricular complexes (PVCs), as seen in Figure 1(ii) and
the regular pacing sequence resumes at 2.4 sec. The appearance of PVC is due to the
change in the repolarisation sequence with endo and mid cells repolarising first,
followed by the epi cells. For the 100 μM HCQ config, the three PBs gives rise to
Current HCQ (1 μM) HCQ (10 μM) HCQ (100 μM)
INa 22% 35% 55%
ICaL 12% 12% 40%
IKr 18% 55% 85%
IK1 10% 20% 80%
HCQ (1 μM) and AZM HCQ (10 μM) and AZM HCQ (100 μM) and AZM
INa 18% 22% 38%
ICaL 10% 15% 30%
IKr 30% 62% 90%
IKs 18% 20% 22%
IK1 10% 30% 82%
Table 3.
Ionic currents for different dosages of HCQ and with AZM represented by in-vitro study [21].
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similar ECG complexes (with positive widened T-waves) as that in usual pacing.
The regular beat resumes after a long pause at 3.3 sec.
Further, on the inclusion of 1 μMAZMwith each of the 1 μM, 10 μM and 100 μM
HCQ config, the QT interval prolongs by 7.14%, 20% and 80% respectively, in the
control ventricle as shown in Figure 1(iii). Likewise, the T-peak increases by 3.87%,
37.5% and 36.63% under AZM in combination with 1 μM, 10 μM and 100 μM HCQ
respectively. However, the QRS duration remains the same in both 1μM and 10 μM
HCQ, but increases by 7.14% in 100 μM HCQ. Additionally, PVCs arise due to the
inclusion of PBs in the combination of 1 μM HCQ and AZM, and regular pulses
resume at 1.6 sec. The occurrence of PVCs increases in the presence of PBs in 10 μM
HCQ, as seen in Figure 1(iv). This effect is due to the change in repolarisation













Control 0.350 0.232 0.070
Mild COVID 0.325 0.152 0.070
severe COVID 0.275 0.170 0.070
1 HCQ Control 0.355 0.208 0.075
1 HCQ Mild COVID 0.330 0.110, 0.124 0.075
1 HCQ severe COVID 0.265 0.206 0.070
1 HCQ with
AZM
Control 0.375 0.24 0.070
1 HCQ with
AZM
Mild COVID 0.350 0.151 0.070
1 HCQ with
AZM
severe COVID 0.285 0.194 0.065
10 HCQ Control 0.390 0.274 0.075
10 HCQ Mild COVID 0.365 0.194 0.075
10 HCQ severe COVID 0.290 0.137 0.070
10 HCQ with
AZM
Control 0.420 0.319 0.070
10 HCQ with
AZM
Mild COVID 0.390 0.227 0.070
10 HCQ with
AZM
severe COVID 0.300 0.119 0.065
100 HCQ Control 0.505 0.230 0.085
100 HCQ Mild COVID 0.450 0.159 0.090
100 HCQ severe COVID 0.345 0.075 0.080
100 HCQ with
AZM
Control 0.630 0.317 0.075
100 HCQ with
AZM
Mild COVID 0.555 0.220 0.075
100 HCQ with
AZM
severe COVID 0.355 0.05 0.070
Table 4.
Surrogate biomarker such as QT interval, T-peak and QRS duration of controlled, mild and severely infected
COVID ventricle in response to various HCQ doses (1, 10 and 100 μM) alone or with 1 μM AZM [21].
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pulses resume at 2.4 sec. Although no reentry is generated in the tissue, the appear-
ance of PVCs is a precursor to the development of arrhythmia. This finding is in line
with the Wang et al., [14], where a dosage of 10 μM HCQ prolonged the APD of
cells but did not induce an arrhythmia in tissue on decreasing the pacing interval.
Further, the combination of HCQ and AZM created arrhythmic activity. Although
no arrhythmic event was generated in the presence of 100 μM HCQ, widened T-
waves occurred. Such broad-based and symmetrical T-waves, usually with
increased amplitude, are termed as hyperacute T-waves and often associated with a
depressed ST are a sign of acute ischemia (Figure 5) [22].
In the mild COVID-19 scenario, the QT interval becomes shortened by 7.14%
(0.325 sec), and the T-peak decreases by 34.48% while the QRS duration remains
unchanged as shown in (Figure 6(i)). While using 1 μM HCQ, the model’s out-
come, Pseudo ECG’s QT interval increases by 1.43% with a double notch T-peak of
0.124 mV and 0.110 mV. For the 10 μM, the pseudo-ECG prolongs the QT interval
and increases the T-peak by 11.42% and 18.10%, respectively. When HCQ dosage is
100 μM, the QT interval raises by 35.71% with a 3.02% T-peak increase and 21.4%
prolongation of QRS duration. However, in the case of 1 μM and 10 μM HCQ, QRS
duration increases by 7.14%. In the arrhythmogenesis test, three reduced duration
PBs are applied; when the first PB is applied; the mid and epi cells in the tissue start
to repolarization due to the excitation from the previous beat, as a consequence, the
wave propagates upward along with the endo and mid-layers, and lastly, it enters
the epi layer of the cardiac tissue. Succeeding that, the wavefront repolarizes from
the endo, mid and epi layer with the cells located at the top of the epi layer
repolarizing last, resulting in an inverted T-wave. During the second PB excitation
(0.8 sec), the wavefront depolarizes the endo and mid-layer but is not able to excite
the epi layer cells as they are in a refractory state and this results in an ST-segment
elevation in the ECG, as indicated in (Figure 6(ii). For the last PB, yet another PVC
occurs and then regular beats resume at 1.6 sec. In the case of 10 μM HCQ, due to
the change in repolarization pattern, PVCs occur, yet they do not lead to the
Figure 5.
Pseudo ECGs generated (i) in control ventricle treated with HCQ, (ii) on pacing with PBs in presence of HCQ,
(iii) in control ventricle treated with HCQ and 1 μM of AZM, (iv) on pacing with PBs in presence of HCQ and
1 μM of AZM.
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formation of re-entrant patterns. When PB’s are applied in 100 μMHCQ setup, ECG
complexes with widened T-waves are observed.
When AZM was supplemented with 1 μM HCQ, 10 μM HCQ and 100 μM HCQ,
the QT interval prolongs by a percentage of 7.14, 18.57 and 65.71 respectively, under
mild COVID conditions (Figure 6(iii)). Furthermore, the T-peak increases by about
31% in the combination of AZM and 10 μM HCQ or 100 μM HCQ in comparison to
mild COVID while there is negligible effect in 1 μM HCQ. Even though the QRS
duration remains unchanged for 1 μM and 10 μM, it increases by 7.14% in 100 μM
HCQ with 1 μM AZM. On pacing with PBs, PVCs occurred in both 1 μM HCQ and
10 μM HCQ conditions, and the regular pulses resume at 1.6 sec as shown in
Figure 6(iv). When AZM is supplied with 100 μM HCQ and on applying PBs, no
arrhythmic activity appeared in spite of the presence of the hyper-acute T-waves.
In severe COVID-19 configuration, the QT interval reduces by 21.48% (0.275 sec)
with a negative T-wave peak of 0.17 mV and QT depression as shown in Figure 6
(v). This negative T-peak episode might be the representation of ischemia, which is
in line with the clinical ECG recordings. [23]. On treating with 1 μM HCQ, the QT
interval reduces by 2.85% in comparison to severe COVID-19 and the negative T-
peak increases by 15.51%. In contrast, under 10 μM HCQ, the QT interval increase
by 4.28%, with a 14.22% reduction in T-peak. When the tissues are treated with 100
μM HCQ, the QT interval prolongs by 20%, with an immense reduction in the T-
peak (i.e.) 40.98% in comparison to severe COVID-19. Here, the QRS duration is
increased by 14.28% in 100 μM HCQ; while remaining unchanged at other dosages.
In severe COVID-19, the inclusion of 1 μM HCQ and premature pacing sequence
creates ECG complexes with increased negative T-peak amplitude due to the
changes in the repolarisation pattern as seen in Figure 2(vi). The regular pulses are
resumed after a long pause at 1.6 sec. In contrast, on including 10 μM HCQ and
pacing the tissue with the first PB, the M-cells at the top of the tissue are still in the
repolarising state. Therefore, the wave travels upwards along with the endo and
mid-layer before entering the epi layer. This creates a change in the repolarisation
pattern with endo cells repolarising first, followed by mid and epi cells. A similar
Figure 6.
Pseudo ECGs generated (i) in mild COVID-19 infected ventricle treated with HCQ, (ii) on pacing the mild
COVID-19 infected ventricle with PBs with HCQ inhibition, (iii) in severe COVID-19 infected ventricle
treated with HCQ, (iv) on pacing the severe COVID-19 infected ventricle tissue with PBs in presence of HCQ.
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activation pattern occurs on applying the second PB. When the third PB endures, the
epi cells are repolarising; thus, the wavefront travels upwards along with the endo
and mid-layer and re-enters the epi layer from the top. Further, the wavefront travels
down along the epi layer and re-enters into the mid and endo layer. This reentrant
activity creates upward and downward pointing QRS complexes, as shown in 6(vi)
and the regular pacing resumes at 2.4 sec following the re-entry termination; for
details, refer the voltage maps video1 provided in the Supplementary session. In the
case of 100 μM HCQ, no arrhythmic activity or PVCs are observed, although flat T-
waves occur, representing the appearance of myocardial ischemia event [24] or
hypokalemia [25]. The above result infers that an inverted T-wave morphology
(representative of ischemia) can be a biomarker for severe COVID-19 screening.
On including AZM, as indicated in Figure 6(vii), the QT interval increases by
2.85%, 7.14% and 22.85% with 1 μM HCQ, 10 μM HCQ and 100 μM HCQ respec-
tively in comparison to severe COVID. The T-peak increases by 10.34% in the
combination of AZM and 1 μM HCQ while it decreases by 21.98% and 51.72% in 10
μM HCQ and 100 μM HCQ respectively. The QRS duration decreases by 7.14%
remains in the combination of AZM and 1 μM or 10 μM HCQ whereas it is
unchanged in combination with 100 μMHCQ. On pacing the tissue with PBS, PVCs
are observed under 1 μM HCQ and 10 μM HCQ while under 100 μM HCQ, no
significant change in the flattened T-waves is observed as seen in as seen in Figure 6
(viii). The voltage maps video2 under 100 μM HCQ and AZM is provided in the
Supplementary session (Figure 7).
5. Pacing sequence influence on arrhythmogenesis
In addition, to earlier pacing sequence, after the first beat is introduced, PBs are
injected, under two condition, a) three unequal PBs with 800 msec (i.e., HR is 75
beats/min) pulse sequence, b) three equal PBs with 600 msec (i.e., HR is 100 beats/
min), tachycardia pulse sequence. In each case, the first PBs duration is determined
Figure 7.
Pseudo ECGs generated (i) in mild COVID-19 infected ventricle treated with HCQ and 1 μM AZM, (ii) on
pacing the mild COVID-19 infected ventricle with PBs in presence of HCQ and 1 μM AZM, (iii)in severe
COVID-19 infected ventricle treated with HCQ and 1 μMAZM, (iv) on pacing the severe COVID-19 infected
ventricle tissue with PBs in presence of HCQ and 1 μM AZM.
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based on the refractory state and re-excitable property of bottom endo cells in the
tissue. Further, the presence of PBs in mild and severe COVID-19 configurations for
various HCQ dosages is applied to examine when an arrhythmia occurs.
Under mild COVID-19 and 1 μM HCQ conditions, three PBs are injected with
reduced duration after the first regular beat. The mid and epi cells are still
repolarizing when the first PB is applied; this causes the depolarization wave to
travel upwards and the endo and mid-layers and later enter the epi layer. Following
depolarization, repolarization occurs in the endo, mid and then epi layer, with the
cells located at the top of the epi layer repolarizing lastly, leading to a premature
ventricular complex (PVC). The depolarization wavefront from the second PB at
0.8-sec proceeds along with the endo and mid layer, however, it cannot excite the
epi layer cells as they are in a refractory state, and this appears as an ST-segment
elevation. Further, the third PB gives rise to another PVC and at 1.6 sec, the regular
beats resume with notched T-waves. For 10 μM HCQ and mild cases, the three PBs
give rise to PVCs due to the change in repolarization pattern, and wavefront reentry
is absent. However, the QT interval and T-peak increase compared to control. ECG
complexes with widened T-waves increased QT interval, and QRS duration is
observed on pacing the tissue with three PBs under mild COVID-19 and 100 μM
HCQ conditions. In severe COVID-19, the inclusion of 1 μM HCQ or 10 μM HCQ
with three PBs for every 245 msec and 265 msec respectively give rise to PVCs with
an increased negative/inverted T-peak. This result could be due to the repolariza-
tion pattern changes. However, in 100 μMHCQ conditions, no significant change is
observed with similar ECG complexes occurring on applying three PBs at a pacing
interval of 460 msec. The normal ECGs resumed at 1.2 sec in all three scenarios.
Thus, the result inferred that an inverted T-wave morphology (representative of
ischemia) could serve as a biomarker for severe COVID-19 conditions.
6. Limitation
In this study, we considered a 2D anisotropic transmural ventricular model, in
which the entire mid-layer is composed of M-cells with longer APD. However,
certain studies have disputed the presence of M-cells [26, 27] and others have
debated that they form islands in the endo-mid interface [28, 29]. Here, arrhythmic
patterns are generated through a premature pacing sequence. Like other few other
studies, [16], here we had not considered using the cross-pacing sequence to simu-
late an arrhythmia, as the propagation pattern would then travel parallel along the
entire length of the ventricle from endo, mid and epi, and it would not mimic the
actual depolarisation pattern in the ventricle and thereby result in irregular pseudo-
ECG wave. Another option is the generic Short-long-short (SLS) pacing sequences
that can initiate TdP pattern [30], which is our future direction. In clinical ECG
recordings, self-terminating re-entrant arrhythmia of few cycles may not be con-
sidered critical. However, the limited duration of the reentry generated here is due
to the consideration of the 2D ventricle model. In a three-dimensional or whole
heart model, sustainable ventricular arrhythmias may occur. Finally, we considered
1 μM, 10 μM, and 100 μM of HCQ and 1 μM AZM dosage due to the ionic current
percentage variation reported by Wang et al., clinical study.
7. Conclusions
This study presents the first complete electrophysiological mechanism of
COVID infected ventricle tissue with and without hypokalemia comorbidities and
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its responses to HCQ treatment. This model strategically allows more direct studies
of ion channel perturbation from clinical observation of infected victims. This
study’s main conclusion is that when healthy cardiac tissue is infected by COVID, it
engenders shorter QT interval, low amplitude or inverted T-waves and ST depres-
sion, which could be used as biomarkers. When treated with HCQ, in case of severe
COVID-19, there is no significant adverse effect, but in mild COVID-19, QT inter-
val prolongs and T-peak increases in ECG. Secondly, COVID-19 withal to the
comorbid cardiac ventricle causes a slight QT interval elongation, notched T-waves
in hypokalemia1, inverted T-waves in the presence of all severe hypoxia. In partic-
ular, the hypokalemic ventricle is prone to arrhythmia in the presence of COVID-19
and the addition of HCQ drug has no significant effects. Increasing the dosage of
HCQ has the effect of prolonging the QT interval, and QRS duration and inclusion
of AZM magnifies this effect. PVCs could be detected on pacing the tissue with PBs
at lower doses of HCQ, and it led to the initiation of reentrant arrhythmia in severe
COVID-19 conditions. Further, the pacing protocol also determines the appearance
of reentry. Thus, the finding of this in-silico model could be considered for HCQ
management in patients with pre-existing pathologies.
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